Assessment of distributions and gender difference in adverse events related to faricimab: a real-world study based on FDA adverse event reporting system

Faricimab is a novel bispecific antibody drug for treating retinal disease. We aim to study the adverse events of faricimab based on the FDA Adverse Event Reporting System (FAERS) database.